<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327111432502</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327111432502</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Studies on the protective effect of flaxseed oil on cisplatin-induced hepatotoxicity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Naqshbandi</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111432502"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khan</surname>
<given-names>W</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111432502"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rizwan</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111432502"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Khan</surname>
<given-names>F</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327111432502"/>
<xref ref-type="corresp" rid="corresp1-0960327111432502"/>
</contrib>
<aff id="aff1-0960327111432502">Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, Uttar Pradesh, India</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0960327111432502">Farah Khan, Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, Uttar Pradesh, India Email: <email>DrFarahKhan23@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>31</volume>
<issue>4</issue>
<fpage>364</fpage>
<lpage>375</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Cisplatin (CP) is known as one of the most potent chemotherapeutic antitumor drugs. The tissue-specific toxicity of CP in the kidneys is well documented. However, at higher doses less common toxic effects such as hepatotoxicity may arise. Since CP remains one of the most effective antineoplastic drug used in chemotherapy, strategies to protect tissues against CP toxicity are of clinical interest. Recently, ω-3 polyunsaturated fatty acids (PUFAs) from certain plants/seeds notably flaxseed have shown numerous health benefits. In view of this, the present study investigates the protective effect of flaxseed oil (FXO) on CP-induced damage in liver. Rats were pre-fed normal diet and the diet rich in FXO for 10 days and then a single dose of CP (6 mg/kg body weight) was administered intraperitoneally while still on diet. Serum/urine parameters, enzymes of carbohydrate metabolism and oxidative stress were analyzed. CP caused perturbation of the antioxidant defense as reflected by the decrease in the activities of catalase, superoxide dismutase and glutathione peroxidase. Further the activities of various enzymes involved in glycolysis, tricarboxylic acid cycle, gluconeogenesis and hexose monophosphate shunt pathways were determined and were found to be differentially altered by CP treatment. However, these alterations were ameliorated in CP-treated rats fed on FXO. Present results show that dietary supplementation of FXO in CP-treated rats ameliorated CP-induced hepatotoxic and other deleterious effects due to its intrinsic biochemical/antioxidant properties.</p>
</abstract>
<kwd-group>
<kwd>cisplatin</kwd>
<kwd>hepatotoxicity</kwd>
<kwd>flaxseed oil</kwd>
<kwd>carbohydrate metabolism</kwd>
<kwd>oxidative stress</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327111432502">
<title>Introduction</title>
<p>Cisplatin (cis-diamminedichloroplatinum II (CP)) is one of the most effective and widely used chemotherapeutic agents in the treatment of a variety of human solid tumors.<sup>
<xref ref-type="bibr" rid="bibr1-0960327111432502">1</xref>
</sup> The CP-induced ototoxicity and nephrotoxicity have been very well studied in both clinical and animal research, however hepatotoxicity has been rarely paid attention to. Recent studies have suggested that hepatotoxicity is also a major dose-limiting side effect in CP-based chemotherapy.<sup>
<xref ref-type="bibr" rid="bibr2-0960327111432502">2</xref>
<xref ref-type="bibr" rid="bibr3-0960327111432502"/>–<xref ref-type="bibr" rid="bibr4-0960327111432502">4</xref>
</sup> Continued aggressive high-dose CP chemotherapy necessitates the investigation of ways for prevention of the dose-limiting side effects that inhibit the CP administration at tumoricidal doses. CP chemotherapy induces a fall in plasma antioxidant levels, which may reflect a failure of the antioxidant defense mechanism against oxidative damage induced by commonly used antitumor drugs.<sup>
<xref ref-type="bibr" rid="bibr5-0960327111432502">5</xref>
</sup> A relationship between oxidative stress and CP toxicity has been suggested in many experimental models. Several reports have implicated free radicals and reactive oxygen species (ROS) in the toxicity of CP. CP-induced toxicity is closely associated with an increase in lipid peroxidation (LPO), decreased levels of protein bound sulfhydryl groups and glutathione which indicate the formation of ROS.<sup>
<xref ref-type="bibr" rid="bibr6-0960327111432502">6</xref>
<xref ref-type="bibr" rid="bibr7-0960327111432502"/>–<xref ref-type="bibr" rid="bibr8-0960327111432502">8</xref>
</sup>
</p>
<p>Until now a large number of studies have been focused on the ways for prevention of CP side effects via supplementation of preventive agents simultaneously.<sup>
<xref ref-type="bibr" rid="bibr9-0960327111432502">9</xref>,<xref ref-type="bibr" rid="bibr10-0960327111432502">10</xref>
</sup> The past 3 decades have been a period of rapid expansion in the scientific knowledge of ω-3 PUFAs. The most common way to consume ω-3 fatty acids has been in the form of marine oils like fish. Studies from our laboratory have shown that dietary fish oil (FO) supplementation ameliorates gentamicin and CP-induced damage to kidney and liver, respectively.<sup>
<xref ref-type="bibr" rid="bibr4-0960327111432502">4</xref>,<xref ref-type="bibr" rid="bibr11-0960327111432502">11</xref>
</sup> Vegetable sources including grains and oils offer an alternative source for those who are unable to regularly consume fish for religious or other reasons.<sup>
<xref ref-type="bibr" rid="bibr12-0960327111432502">12</xref>
</sup> Flaxseed (<italic>Linum usitatissimum</italic>) is the richest dietary sources of ω-3 among plant sources. Recently flaxseed has been identified as a significant alternative source of ω-3 fatty acids.<sup>
<xref ref-type="bibr" rid="bibr13-0960327111432502">13</xref>,<xref ref-type="bibr" rid="bibr14-0960327111432502">14</xref>
</sup> Dietary supplementation with flaxseed oil (FXO) affects the biochemistry of fatty acid metabolism and thus the balance of proinflammatory mediators and atherogenic lipids, holding a great promise for modulating inflammatory diseases.<sup>
<xref ref-type="bibr" rid="bibr15-0960327111432502">15</xref>
</sup> FXO has also been shown to increase the life span of irradiated mice, suggesting its prophylactic potential against radiation-induced degenerative changes in liver.<sup>
<xref ref-type="bibr" rid="bibr16-0960327111432502">16</xref>
</sup> However, the protective effect of FXO on CP-induced toxicity has not yet been investigated.</p>
<p>Taking into consideration the potential clinical use of CP and numerous health benefits of FXO, the present work was undertaken to study the detailed biochemical events/cellular response/mechanisms of CP-induced hepatotoxicity and its protection by dietary FXO. We hypothesized that FXO would prevent CP-induced hepatotoxicity due to its intrinsic biochemical and antioxidant properties that would lead to improved metabolism and antioxidant defense mechanism of the liver. The results obtained indicate that dietary supplementation with FXO markedly ameliorated CP-induced adverse effects in liver. The activities of carbohydrate metabolism, membrane and antioxidant enzymes were markedly enhanced by FXO feeding to CP-administered rats. These studies support a potential therapeutic use of CP + FXO combination in combating cancer without hepatotoxic and other harmful side effects.</p>
</sec>
<sec id="section2-0960327111432502">
<title>Materials and methods</title>
<sec id="section3-0960327111432502">
<title>Chemicals and drugs</title>
<sec id="section4-0960327111432502">
<title>Flaxseed oil</title>
<p>Omega Nutrition Canada Inc., Cisplatin (Sigma Chemical Co., USA). All other chemicals used were of analytical grade and were purchased either from Sigma Chemical Co. (St Louis, MO, USA) or from SRL, Mumbai, India.</p>
</sec>
</sec>
<sec id="section5-0960327111432502">
<title>Diet</title>
<p>A nutritionally adequate laboratory pellet diet was obtained from Aashirwaad Industries, Chandigarh (India). Pellets were crushed finely and mixed with 15% FXO and stored in airtight containers. Vitamin E as <sc>dl</sc>-α-tocopherol (270 mg/kg chow) was added to each of the modified rat chows in order to meet the increased metabolic requirement for antioxidants on a diet high in PUFAs.</p>
</sec>
<sec id="section6-0960327111432502">
<title>Experimental design</title>
<p>The animal experiments were conducted according to the guidelines of Committee for Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forests, Government of India. Adult male Wistar rats (8 rats/group) weighing between 150 and 200 g were used in the study. Animals were acclimatized to the animal facility for a week on standard rat chow and allowed water ad libitum under controlled conditions of 25 ± 2°C temperature, 50 ± 15% relative humidity and normal photoperiod (12 h dark and light). Four groups of rats entered the study after acclimatization (<xref ref-type="fig" rid="fig1-0960327111432502">Figure 1</xref>). They were fed on either normal diet (control and CP groups) or diet containing 15% FXO (CPFXO and FXO groups). After 10 days, rats in 2 groups (CP and CPFXO) were administered a single dose of CP intraperitoneally (6 mg/kg body weight) in 0.9% saline. Animals in the control and FXO group received an equivalent amount of normal saline. The rats were killed 4 days after CP administration under light ether anesthesia. Blood and urine samples were collected and liver was removed and processed for the preparation of homogenate as described below. All the preparations and analyses of various parameters were performed simultaneously under similar experimental conditions to avoid any day-to-day variations. Body weights of rats were recorded at the start and completion of the experimental procedures.</p>
<fig id="fig1-0960327111432502" position="float">
<label>Figure 1.</label>
<caption>
<p>Experimental design (ND: normal diet, C: control, FXO: flaxseed oil diet, CP: cisplatin, CPFXO: flaxseed oil + cisplatin treated, i.p.: intraperitoneal; CP injection (⇑); normal saline injection (↑).</p>
</caption>
<graphic alternate-form-of="fig1-0960327111432502" xlink:href="10.1177_0960327111432502-fig1.tif"/>
</fig>
</sec>
<sec id="section7-0960327111432502">
<title>Preparation of homogenates</title>
<p>After the completion of treatment schedule, animals were killed, liver was carefully removed from the treated and control animals and homogenized in 0.1 M Tris-HCl buffer (pH 7.5) by a glass-teflon homogenizer (Thomas PA, USA) by passing 5 pulses; at 4°C to make a 10% (w/v) homogenate. The homogenate was then subjected to high-speed Ultra-Turrex Kunkel homogenizer (Type T-25, Janke &amp; Kunkel GMBH &amp; Co. KG. Staufen, Germany) for 3 strokes of 30 s each with an interval of 30 s between each stroke. Homogenate was centrifuged at 2000 r/min at 4°C for 10 min in Beckman J2-M1 (Beckman instruments, Inc Palo Alto, CA, USA) high-speed refrigerated centrifuge to remove the cell debris. The aliquots of homogenates were saved and stored at --20°C for various enzyme activities.</p>
</sec>
<sec id="section8-0960327111432502">
<title>Serum/urine chemistries</title>
<p>Serum samples were deproteinated with 3% trichloroacetic acid in a ratio of 1:3, left for 10 min and then centrifuged at 2000<italic>g</italic> for 10 min. The protein free supernatant was used to determine inorganic phosphate (Pi) and creatinine. The precipitate was used to quantitate total phospholipids (PLs). Blood urea nitrogen (BUN) and cholesterol levels were determined directly in serum samples. These parameters were determined by standard procedures as mentioned in a previous study.<sup>
<xref ref-type="bibr" rid="bibr17-0960327111432502">17</xref>
</sup> Transaminases, alanine aminotransferase (ALT) and aspartate aminotransferases (AST) were estimated by Reitman and Frankel method using kit from span diagnostics. Glucose was estimated by <italic>o</italic>-toluidene method using kit from Span diagnostics, Mumbai, India.</p>
</sec>
<sec id="section9-0960327111432502">
<title>Assay of carbohydrate metabolism enzymes</title>
<p>The activities of the enzymes involving oxidation of nicotinamide adenine dinucleotide or reduction of nicotinamide adenine dinucleotide phosphate (NADP) were determined spectrophotometrically on Cintra 5 fixed for 340 nm using 3 ml of assay in a 1-cm cuvette at room temperature (28–30°C). The enzyme activities of lactate dehydrogenase (LDH, E.C.1.1.1.27), malate dehydrogenase (MDH, E.C.1.1.1.37), malic enzyme (ME, E.C.1.1.1.40), glucose-6-phosphate dehydrogenase (G6PDH, E.C.1.1.1.49), glucose-6-phosphatase (G6Pase, E.C.3.1.3.3) and fructose-1,6-bisphosphatase (FBPase, E.C.3.1.3.11) were assayed as described by Khundmiri et al.<sup>
<xref ref-type="bibr" rid="bibr17-0960327111432502">17</xref>
</sup> Hexokinase (HK) was estimated by the method of Crane and Sols<sup>
<xref ref-type="bibr" rid="bibr18-0960327111432502">18</xref>
</sup> and the remaining glucose was measured by method of Nelson.<sup>
<xref ref-type="bibr" rid="bibr19-0960327111432502">19</xref>
</sup>
</p>
</sec>
<sec id="section10-0960327111432502">
<title>Assay of membrane enzymes and lysosomal marker enzyme</title>
<p>The activities of membrane marker enzymes, alkaline phosphatase (ALP), leucine amino peptidase (LAP), γ-glutamyl transferase (GGTase) and lysosomal marker enzyme, acid phosphatase (ACPase) were determined as described by Farooq et al.<sup>
<xref ref-type="bibr" rid="bibr20-0960327111432502">20</xref>
</sup>
</p>
</sec>
<sec id="section11-0960327111432502">
<title>Assay of enzymes involved in free radical scavenging</title>
<p>Superoxide dismutase (SOD, E.C.1.15.1.1) was assayed by the method of Marklund and Marklund.<sup>
<xref ref-type="bibr" rid="bibr21-0960327111432502">21</xref>
</sup> Catalase (CAT, E.C.1.11.1.6) and glutathione peroxidase (GSH-Px, E.C. 1.11.1.9) activities were assayed by the method of Giri et al.<sup>
<xref ref-type="bibr" rid="bibr22-0960327111432502">22</xref>
</sup> and Flohe and Gunzler,<sup>
<xref ref-type="bibr" rid="bibr23-0960327111432502">23</xref>
</sup> respectively.</p>
</sec>
<sec id="section12-0960327111432502">
<title>Lipid peroxidation and total –SH group estimation</title>
<p>Total SH groups were determined by the method of Sedlak and Lindsay<sup>
<xref ref-type="bibr" rid="bibr24-0960327111432502">24</xref>
</sup> and LPO by the method of Ohkawa et al.<sup>
<xref ref-type="bibr" rid="bibr25-0960327111432502">25</xref>
</sup>
</p>
</sec>
<sec id="section13-0960327111432502">
<title>Statistical analyses</title>
<p>All data are expressed as mean ± SEM for at least 4–5 different preparations. Statistical evaluation was conducted by one-way analysis of variance (ANOVA) using Origin 6.1 software. A probability level of <italic>p</italic> &lt; 0.05 was selected as indicating statistical significance. Most of the changes between various groups were compared with control values for better understanding and clarity.</p>
</sec>
</sec>
<sec id="section14-0960327111432502">
<title>Results</title>
<p>The present work was undertaken to study detailed mechanism of CP-induced hepatotoxicity and other deleterious effects and its possible protection by feeding ω-3 fatty acids–enriched diet to the rats. To address our hypothesis, the effect of CP alone and in combination with FXO, a rich source of ω-3 fatty acids, was determined on various enzymatic and nonenzymatic parameters of oxidative stress and enzymes of carbohydrate metabolism in rat liver.</p>
<sec id="section15-0960327111432502">
<title>Effect of dietary FXO oil on CP-induced alterations in serum and urinary parameters</title>
<p>Results summarized in <xref ref-type="table" rid="table1-0960327111432502">Tables 1</xref> and <xref ref-type="table" rid="table2-0960327111432502">2</xref> show the effect of CP alone and in combination with FXO on blood and urine chemistries.</p>
<table-wrap id="table1-0960327111432502" position="float">
<label>Table 1.</label>
<caption>
<p>Effect of flaxseed oil (FXO) on serum parameters with or without CP treatment<sup><xref ref-type="table-fn" rid="table-fn2-0960327111432502">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table1-0960327111432502" xlink:href="10.1177_0960327111432502-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="8">Group</th>
</tr>
<tr>
<th>Groups</th>
<th>Creatinine (mg/dl)</th>
<th>BUN (mg/dl)</th>
<th>ALT (IU/L)</th>
<th>AST (IU/L)</th>
<th>Cholesterol (mg/dl)</th>
<th>Phospholipid (mg/dl)</th>
<th>Phosphate (μmol/ml)</th>
<th>Glucose (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.942 ± 0.080</td>
<td>16.49 ± 1.16</td>
<td>28.39 ± 0.58</td>
<td>62.32 ± 3.88</td>
<td>51.27 ± 0.66</td>
<td>23 ± 2.3</td>
<td>3.59 ± 0.11</td>
<td>73.51 ± 0.01</td>
</tr>
<tr>
<td>CP</td>
<td>2.60 ± 0.142<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup>  (+176%)</td>
<td>36.66 ± 0.70<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (+122%)</td>
<td>58.52 ± 3.74<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (+106%)</td>
<td>158.4 ± 13.8<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn4-0960327111432502">c</xref></sup> (+154%)</td>
<td>58.08 ± 1.86<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup>  (+13%)</td>
<td>40.82 ± 1.15<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (+77%)</td>
<td>2.97 ± 0.150  (−17%)</td>
<td>15.21 ± 2.79<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (−79%)</td>
</tr>
<tr>
<td>CPFXO</td>
<td>1.13 ± 0.032<sup><xref ref-type="table-fn" rid="table-fn4-0960327111432502">c</xref></sup>  (+20%)</td>
<td>30.42 ± 1.45<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (+84%)</td>
<td>37.30 ± 1.91<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn4-0960327111432502">c</xref></sup> (+31%)</td>
<td>143 ± 4.9<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn4-0960327111432502">c</xref></sup> (+129%)</td>
<td>42.62 ± 2.33<sup><xref ref-type="table-fn" rid="table-fn4-0960327111432502">c</xref></sup>  (−17%)</td>
<td>54.33 ± 0.862<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn4-0960327111432502">c</xref></sup> (+136%)</td>
<td>3.03 ± 0.025<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup>  (−16%)</td>
<td>36.67 ± 1.45<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn4-0960327111432502">c</xref></sup> (−50%)</td>
</tr>
<tr>
<td>FXO</td>
<td>0.686 ± 0.018<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (−27%)</td>
<td>19.64 ± 0.714 (+19%)</td>
<td>31.09 ± 1.49 (+10%)</td>
<td>80.29 ± 3.61<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (+29%)</td>
<td>3.79 ± 0.438<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup>  (−93%)</td>
<td>16.96 ± 0.29<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (−26%)</td>
<td>3.28 ± 0.114  (−9%)</td>
<td>64.77 ± 0.30<sup><xref ref-type="table-fn" rid="table-fn3-0960327111432502">b</xref></sup> (−12%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327111432502">
<p>CP: cisplatin treated; CPFXO: flaxseed oil + cisplatin treated; FXO: flaxseed oil diet; BUN: blood urea nitrogen; ALT: alanine aminotransferases; AST: aspartate aminotransferases.</p>
</fn>
<fn id="table-fn2-0960327111432502">
<p>
<sup>a</sup>Results are mean ± SEM for five different experiments.</p>
</fn>
<fn id="table-fn3-0960327111432502">
<p>
<sup>b</sup>Significantly different from control at <italic>p</italic> &lt; 0.05 by one-way ANOVA. Values in parentheses represent percent change from control.</p>
</fn>
<fn id="table-fn4-0960327111432502">
<p>
<sup>c</sup>Significantly different from CP at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0960327111432502" position="float">
<label>Table 2.</label>
<caption>
<p>Effect of flaxseed (FXO) on urine parameters with/without CP treatment<sup><xref ref-type="table-fn" rid="table-fn6-0960327111432502">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table2-0960327111432502" xlink:href="10.1177_0960327111432502-table2.tif"/>
<table>
<thead>
<tr>
<th>Groups</th>
<th>Urine flow rate (UFR; ml/day)</th>
<th>Creatinine clearance (ml/min/100 g bwt)</th>
<th>Phosphate (μmol/ml)</th>
<th>Protein (mg/mmol creatinine)</th>
<th>Glucose (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>8.4 ± 1.15</td>
<td>0.22 ± 0.001</td>
<td>0.462 ± 0.005</td>
<td>1.25 ± 0.026</td>
<td>22.37 ± 1.73</td>
</tr>
<tr>
<td>CP</td>
<td>18 ± 1.73<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref></sup> (+114%)</td>
<td>0.032 ± 0.011<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref></sup> (−85%)</td>
<td>0.680 ± 0.115 (+47%)</td>
<td>1.97 ± 0.005<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref></sup> (+58%)</td>
<td>104.1 ± 0.0057<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn8-0960327111432502">c</xref></sup> (+365%)</td>
</tr>
<tr>
<td>CPFXO</td>
<td>13.2 ± 0.57<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn8-0960327111432502">c</xref></sup> (+57%)</td>
<td>0.067 ± 0.017<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn8-0960327111432502">c</xref></sup> (−70%)</td>
<td>0.595 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref></sup> (+29%)</td>
<td>1.78 ± 0.23 (+42%)</td>
<td>65.75 ± 2.88<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn8-0960327111432502">c</xref></sup> (+194%)</td>
</tr>
<tr>
<td>FXO</td>
<td>6 ± 0.115 (−29%)</td>
<td>0.258 ± 0.0023<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref></sup>(+17%)</td>
<td>0.261 ± 0.001<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref></sup> (−43%)</td>
<td>0.740 ± 0.115<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref></sup> (−41%)</td>
<td>35.61 ± 0.570<sup><xref ref-type="table-fn" rid="table-fn7-0960327111432502">b</xref></sup> (+59%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0960327111432502">
<p>CP: cisplatin treated; CPFXO: flaxseed oil + cisplatin treated; FXO: flaxseed oil diet.</p>
</fn>
<fn id="table-fn6-0960327111432502">
<p>
<sup>a</sup>Results are mean ± SEM for five different experiments. Values in parentheses represent percent change from control.</p>
</fn>
<fn id="table-fn7-0960327111432502">
<p>
<sup>b</sup>Significantly different from control at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
<fn id="table-fn8-0960327111432502">
<p>
<sup>c</sup>Significantly different from CP at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The liver dysfunction induced by CP was characterized by the elevated levels of serum transaminases, ALT and AST. CP treatment to control rats resulted in significant increase in serum transaminases (ALT, +106% and AST, +154%), creatinine (Scr, +176%), BUN (+122.31%) and PL (+77%) but decrease in Pi (−17%) and glucose (−79%) compared to control rats. These changes were associated with profound phosphaturia, proteinuria and glucosuria accompanied by decreased creatinine clearance. FXO diet alone caused decrease in Scr, cholesterol and PL accompanied by significant increase in creatinine clearance.</p>
<p>Dietary supplementation of FXO diet prior to and following CP administration resulted in significant reversal of various CP-elicited deleterious effects on serum and urine parameters. FXO prevented CP-induced increase in transaminases, Scr and BUN.</p>
</sec>
<sec id="section16-0960327111432502">
<title>Effect of dietary FXO on CP-induced alterations in membrane enzymes and marker enzyme of lysosomes</title>
<p>To assess the structural integrity of plasma membrane and lysosomes, the effect of CP alone and in combination with FXO diet was determined on membrane and lysosomal enzymes in the liver homogenate (<xref ref-type="fig" rid="fig2-0960327111432502">Figure 2</xref>). The activities of membrane marker enzymes viz ALP, GGTase and LAP and lysosomal marker enzyme, ACPase, were determined under different experimental conditions in the homogenates of liver (<xref ref-type="table" rid="table3-0960327111432502">Table 3</xref>). CP treatment to control rats caused significant reduction in the specific activities of ALP (−64%), GGTase (−39%) and LAP (−37%) in liver homogenate. CP treatment to FXO fed rats prevented CP elicited decrease in membrane enzyme activities. As can be seen from the data, CP-induced decrease in enzyme activities were prevented by FXO diet. However, the activity of ACPase was increased (+54%) by CP treatment in liver homogenate, while FXO diet was able to prevent the increase in ACPase activity (<xref ref-type="table" rid="table3-0960327111432502">Table 3</xref>).</p>
<fig id="fig2-0960327111432502" position="float">
<label>Figure 2.</label>
<caption>
<p>Effect of flaxseed oil (FXO) on the activities of alkaline phosphatase (ALP), γ-glutamyl transferase (GGTase), leucine amino peptidase (LAP) and acid phosphatase (ACPase) in liver homogenate with CP treatment. Results (μmol/mg protein/h) are mean ± SEM for five different preparations. *Significantly different from control, †significantly different from CP: at <italic>p</italic> &lt; 0.05 by one-way analysis of variance (ANOVA).</p>
</caption>
<graphic alternate-form-of="fig2-0960327111432502" xlink:href="10.1177_0960327111432502-fig2.tif"/>
</fig>
<table-wrap id="table3-0960327111432502" position="float">
<label>Table 3.</label>
<caption>
<p>Effect of flaxseed oil (FXO) on biomarker enzymes of membrane and lysosomes with/without CP treatment in liver homogenates<sup><xref ref-type="table-fn" rid="table-fn10-0960327111432502">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table3-0960327111432502" xlink:href="10.1177_0960327111432502-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="4">Enzyme</th>
</tr>
<tr>
<th>Groups</th>
<th align="center">ALP (μmol/mg protein/h)</th>
<th align="center">GGTase (μmol/mg protein/h)</th>
<th align="center">LAP (μmol/mg protein/h)</th>
<th align="center">ACPase (μmol/mg protein/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5.18 ± 0.430</td>
<td>2.41 ± 0.1</td>
<td>12.44 ± 0.231</td>
<td>1.40 ± 0.025</td>
</tr>
<tr>
<td>CP</td>
<td>1.85 ± 0.05<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref></sup> (−64%)</td>
<td>1.47 ± 0.032<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref></sup> (−39%)</td>
<td>7.89 ± 0.35<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref></sup> (−37%)</td>
<td>2.16 ± 0.08<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref></sup> (+54%)</td>
</tr>
<tr>
<td>CPFXO</td>
<td>2.93 ± 0.262<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn12-0960327111432502">c</xref></sup> (−43%)</td>
<td>1.87 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn12-0960327111432502">c</xref></sup> (−22%)</td>
<td>10.78 ± 0.19<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn12-0960327111432502">c</xref></sup> (−13%)</td>
<td>1.77 ± 0.109<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref></sup> (+26%)</td>
</tr>
<tr>
<td>FXO</td>
<td>5.17 ± 0.241 (−0.16%)</td>
<td>3.78 ± 0.168<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref></sup> (+57%)</td>
<td>13.98 ± 0.27<sup><xref ref-type="table-fn" rid="table-fn11-0960327111432502">b</xref></sup> (+12%)</td>
<td>1.23 ± 0.092 (−12%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0960327111432502">
<p>CP: cisplatin treated; CPFXO: flaxseed oil + cisplatin treated; FXO: flaxseed oil diet; ALP: alkaline phosphatase; GGTase: γ-glutamyl transferase; LAP: leucine amonipeptidase; ACPase: acid phosphatase.</p>
</fn>
<fn id="table-fn10-0960327111432502">
<p>
<sup>a</sup>Results (specific activity expressed as μmoles/mg protein/h) are mean ± SEM for five different experiments. Values in parentheses represent percent change from control.</p>
</fn>
<fn id="table-fn11-0960327111432502">
<p>
<sup>b</sup>Significantly different from control at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
<fn id="table-fn12-0960327111432502">
<p>
<sup>c</sup>Significantly different from CP at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section17-0960327111432502">
<title>Effect of FXO on CP-induced alterations on metabolic enzymes in liver</title>
<p>The effect of CP, FXO diet and their combined treatment was determined by the activities of various enzymes of carbohydrate metabolism in liver. As shown in <xref ref-type="table" rid="table4-0960327111432502">Table 4</xref>, CP treatment to control rats significantly increased the activities of LDH (+104.76%), HK (+18%) and ME (+52%) but decreased the activities of MDH (−33%), G6Pase (−22), FBPase (−44%) and G6PDH (−49%). In contrast, FXO consumption enhanced the activities of FBPase and G6Pase. Feeding FXO to CP-treated rats arrested CP-induced decline in MDH, FBPase, G6Pase, G6PDH activities and enhancement in LDH, HK and ME activities.</p>
<table-wrap id="table4-0960327111432502" position="float">
<label>Table 4.</label>
<caption>
<p>Effect of flaxseed oil (FXO) on carbohydrate metabolic enzymes with/without CP treatment in liver homogenates<sup><xref ref-type="table-fn" rid="table-fn14-0960327111432502">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table4-0960327111432502" xlink:href="10.1177_0960327111432502-table4.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="7">Group</th>
</tr>
<tr>
<th>Groups</th>
<th>LDH (μmol/mg protein/h)</th>
<th>MDH (μmol/mg protein/h)</th>
<th>HK (mmol/mg protein/h)</th>
<th>G6Pase (mmol/mg protein/h)</th>
<th>FBPase (mmol/mg protein/h)</th>
<th>ME (mmol/mg protein/h)</th>
<th>G6PDH (mmol/mg protein/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1.05 ± 0.042</td>
<td>1.46 ± 0.1</td>
<td>1.08 ± 0.07</td>
<td>0.339 ± 0.004</td>
<td>2.13 ± 0.07</td>
<td>0.021 ± 0.002</td>
<td>0.116 ± 0.0028</td>
</tr>
<tr>
<td>CP</td>
<td>2.15 ± 0.09<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup> (+105%)</td>
<td>0.985 ± 0.004<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup>  (−33%)</td>
<td>1.27 ± 0.215   (+18%)</td>
<td>0.264 ± 0.003<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup>  (−22%)</td>
<td>1.19 ± 0.069<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup>  (−44%)</td>
<td>0.032 ± 0.021<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup>  (+52%)</td>
<td>0.059 ± 0.002<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup>  (−49%)</td>
</tr>
<tr>
<td>CPFXO</td>
<td>0.823 ± 0.023<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn16-0960327111432502">c</xref></sup> (−22%)</td>
<td>1.16 ± 0.037<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn16-0960327111432502">c</xref></sup>  (−21%)</td>
<td>1.19 ± 0.051   (+10%)</td>
<td>0.287 ± 0.047  (−15%)</td>
<td>1.57 ± 0.06<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn16-0960327111432502">c</xref></sup>  (−26%)</td>
<td>0.024 ± 0<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">c</xref></sup>  (+14%)</td>
<td>0.082 ± 0.019<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn16-0960327111432502">c</xref></sup>  (−29%)</td>
</tr>
<tr>
<td>FXO</td>
<td>0.447 ± 0.068<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup> (−57%)</td>
<td>1.44 ± 0.130  (−1%)</td>
<td>0.98 ± 0.036   (−9%)</td>
<td>0.364 ± 0.017  (+7%)</td>
<td>2.82 ± 0.092<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup>  (+32%)</td>
<td>0.013 ± 0.001<sup><xref ref-type="table-fn" rid="table-fn15-0960327111432502">b</xref></sup>  (−38%)</td>
<td>0.108 ± 0.003  (−7%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn13-0960327111432502">
<p>CP: cisplatin treated; CPFXO: flaxseed oil + cisplatin treated; FXO: flaxseed oil diet; LDH: lactate dehydrogenase; MDH: malate dehydrogenase; HK: hexokinase; G6Pase: glucose-6-phosphatase; FBPase: fructose-1,6-bisphosphatase; G6PDH: glucose-6-phosphatase dehydrgenase; ME: malic enzyme.</p>
</fn>
<fn id="table-fn14-0960327111432502">
<p>
<sup>a</sup>Results are mean ± SEM for five different experiments. Values in parentheses represent percent change from control.</p>
</fn>
<fn id="table-fn15-0960327111432502">
<p>
<sup>b</sup>Significantly different from control at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
<fn id="table-fn16-0960327111432502">
<p>
<sup>c</sup>Significantly different from CP at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section18-0960327111432502">
<title>Effect of dietary FXO on CP-induced alterations in antioxidant defense parameters in liver</title>
<p>It is evident that ROS generated by various toxicants are important mediators of cellular injury and pathogenesis of various diseases.<sup>
<xref ref-type="bibr" rid="bibr26-0960327111432502">26</xref>
</sup> Antioxidant status is a potential biomarker to determine the physiological state of the cell, tissue or organ. To ascertain the role of antioxidant system in CP-induced toxicity, the effect of CP was observed on oxidative stress parameters. CP enhanced LPO and significantly altered antioxidant enzymes albeit differently (<xref ref-type="table" rid="table5-0960327111432502">Table 5</xref>). LPO measured in terms of malondialdehyde levels significantly enhanced in the (+52%), whereas total –SH declined in the liver (−30%) in CP group. CP treatment caused decrease in SOD (−15%), GSH-Px (−76%) and CAT (−69%) activities. In contrast, FXO consumption increased the activities of antioxidant enzymes albeit to different extents. However, when CP treatment was extended to FXO fed rats (CPFXO group), the decline in SOD, GSH-Px and CAT activities was reduced significantly in comparison to CP group. The results indicate marked protection by FXO diet against CP-induced oxidative damage to renal tissues.</p>
<table-wrap id="table5-0960327111432502" position="float">
<label>Table 5.</label>
<caption>
<p>Effect of flaxseed oil (FXO) on enzymatic and nonenzymatic antioxidant parameters with/without CP treatment in liver homogenates<sup><xref ref-type="table-fn" rid="table-fn18-0960327111432502">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table5-0960327111432502" xlink:href="10.1177_0960327111432502-table5.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="5">Parameters</th>
</tr>
<tr>
<th>Groups</th>
<th>Lipid peroxidation (nmol/g tissue)</th>
<th>Total SH (µmol/g tissue)</th>
<th>SOD (µmol/mg protein)</th>
<th>Catalase (µmol/mg protein/min)</th>
<th>GSH-Px (µmol/mg protein/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>96.22 ± 3.92</td>
<td>15.26 ± 0.38</td>
<td>74.11 ± 3.79</td>
<td>2.46 ± 0.11</td>
<td>0.116 ± 0.002</td>
</tr>
<tr>
<td>CP</td>
<td>145.89 ± 1.68<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup> (+52%)</td>
<td>10.66 ± 0.32<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup> (−30%)</td>
<td>63.17 ± 3.59<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn20-0960327111432502">c</xref></sup> (−15%)</td>
<td>0.753 ± 0.126<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup> (−70%)</td>
<td>0.028 ± 0.0012<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup> (−76%)</td>
</tr>
<tr>
<td>CPFXO</td>
<td>114.41 ± 1.34<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn20-0960327111432502">c</xref></sup> (+19%)</td>
<td>14.50 ± 0.89 (−5%)</td>
<td>69.37 ± 3.59<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn20-0960327111432502">c</xref></sup> (−6%)</td>
<td>1.85 ± 0.135<sup><xref ref-type="table-fn" rid="table-fn20-0960327111432502">c</xref></sup> (−25%)</td>
<td>0.086 ± 0.0057<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref>,<xref ref-type="table-fn" rid="table-fn20-0960327111432502">c</xref></sup> (−26%)</td>
</tr>
<tr>
<td>FXO</td>
<td>50.51 ± 2.52<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup> (−47%)</td>
<td>17.96 ± 0.317<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup> (+18%)</td>
<td>83.67 ± 1.54<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup>(+13%)</td>
<td>3.63 ± 0.07<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup> (+48%)</td>
<td>0.138 ± 0.0029<sup><xref ref-type="table-fn" rid="table-fn19-0960327111432502">b</xref></sup> (+19%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn17-0960327111432502">
<p>CP: cisplatin treated; CPFXO: flaxseed oil + cisplatin treated; FXO: flaxseed oil diet; GSH-Px: glutathione peroxidase; LPO: lipid peroxidation; SOD: superoxide dismutase; total –SH: sulfhydryl groups.</p>
</fn>
<fn id="table-fn18-0960327111432502">
<p>
<sup>a</sup>Results are mean ± SEM for five different experiments. Values in parentheses represent percent change from control.</p>
</fn>
<fn id="table-fn19-0960327111432502">
<p>
<sup>b</sup>Significantly different from control at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
<fn id="table-fn20-0960327111432502">
<p>
<sup>c</sup>Significantly different from CP at <italic>p</italic> &lt; 0.05 by one-way ANOVA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section19-0960327111432502">
<title>Discussion</title>
<p>CP is a major antineoplastic drug used for the treatment of various forms of cancers.<sup>
<xref ref-type="bibr" rid="bibr27-0960327111432502">27</xref>,<xref ref-type="bibr" rid="bibr28-0960327111432502">28</xref>
</sup> The efficacy of CP is limited, however, by its dose-limiting nephrotoxicity.<sup>
<xref ref-type="bibr" rid="bibr29-0960327111432502">29</xref>
<xref ref-type="bibr" rid="bibr30-0960327111432502"/>–<xref ref-type="bibr" rid="bibr31-0960327111432502">31</xref>
</sup> Although CP-induced nephrotoxicity has been very well documented in clinical oncology, hepatotoxicity has been rarely characterized and is less studied. It is known that CP is significantly taken up in human liver and that high doses of the drug produces hepatotoxicity.<sup>
<xref ref-type="bibr" rid="bibr32-0960327111432502">32</xref>,<xref ref-type="bibr" rid="bibr33-0960327111432502">33</xref>
</sup> The treatment of tumor cells with CP provokes several responses including membrane peroxidation, dysfunction of mitochondria, inhibition of protein synthesis and DNA damage.<sup>
<xref ref-type="bibr" rid="bibr34-0960327111432502">34</xref>,<xref ref-type="bibr" rid="bibr35-0960327111432502">35</xref>
</sup> Formation of free radicals leading to oxidative stress has been shown to be one of the pathogenic mechanisms of the adverse effects of CP in kidney and liver.<sup>
<xref ref-type="bibr" rid="bibr36-0960327111432502">36</xref>
</sup> CP is known to cause histopathological and ultrastructural abnormalities in the liver including inflammatory infiltration, hyperplasia, periportal fibrosis, marked disruption of hepatic cords and dilated blood sinusoids. Many hepatocytes showed karyomegaly and pyknotic nuclei indicating apoptosis.<sup>
<xref ref-type="bibr" rid="bibr37-0960327111432502">37</xref>,<xref ref-type="bibr" rid="bibr38-0960327111432502">38</xref>
</sup> Several strategies and agents were utilized to prevent CP-induced toxicity but were not found suitable for clinical practice.<sup>
<xref ref-type="bibr" rid="bibr39-0960327111432502">39</xref>
<xref ref-type="bibr" rid="bibr40-0960327111432502"/>–<xref ref-type="bibr" rid="bibr41-0960327111432502">41</xref>
</sup>
</p>
<p>The last 3 decades have witnessed a major drift in the scientific community toward the roles of naturally occurring dietary substances for their ability to confer health and physiological benefits. A number of studies have revealed that ω-3 PUFAs have numerous health benefits. The predominant dietary sources of PUFA are plants/seed namely flaxseed and fish/marine foods. ω-3 PUFA-enriched FO has received a great deal of attention as therapeutic options in a variety of clinical situations.<sup>
<xref ref-type="bibr" rid="bibr4-0960327111432502">4</xref>,<xref ref-type="bibr" rid="bibr42-0960327111432502">42</xref>,<xref ref-type="bibr" rid="bibr43-0960327111432502">43</xref>
</sup> Lately, flaxseed (<italic>L. usitatissimum</italic>) has been the focus of increased interest in the field of diet and disease research due to the potential health benefits<sup>
<xref ref-type="bibr" rid="bibr44-0960327111432502">44</xref>
</sup> associated with its biologically active component viz ω-3 PUFA. FXO has been shown to prevent lipid disorders and lead-induced neurotoxicity and nephrotoxicity.<sup>
<xref ref-type="bibr" rid="bibr45-0960327111432502">45</xref>,<xref ref-type="bibr" rid="bibr46-0960327111432502">46</xref>
</sup> However, the role of FXO in preventing drug-induced toxicity has not yet been investigated.</p>
<p>The present work was undertaken to study detailed mechanism of CP-induced hepatotoxic alterations and possible role of FXO in preventing those deleterious changes in rat liver. Single CP injection caused marked alterations in serum and urine parameters. The present results show that CP administration to control rats caused hepatotoxicity as indicated by elevated levels of transaminases (ALT and AST). Moreover, Scr and BUN were also enhanced with significant decrease in creatinine clearance. These results also show a significant decrease in serum glucose, Pi, PLs and serum cholesterol, accompanied by massive proteinuria, glucosuria and phosphaturia. FXO diet given prior to and following CP administration prevented CP-induced alterations in various serum/urine parameters. Dietary supplementation of FXO prior to and following CP treatment prevented CP elicited increase in levels of Scr, BUN and transaminases. Serum glucose, PLs and phosphate were improved upon CP treatment to FXO fed rats.</p>
<p>Since the brush border membrane of renal proximal tubules has been shown as the major site of CP-induced renal injury,<sup>
<xref ref-type="bibr" rid="bibr47-0960327111432502">47</xref>,<xref ref-type="bibr" rid="bibr48-0960327111432502">48</xref>
</sup> the integrity of the membrane was assessed by the status of its biomarker enzymes ALP, GGTase and LAP. CP significantly decreased the activities of ALP, GGTase and LAP in the liver homogenate. The decrease in membrane enzyme activities might have occurred due to the loss of membrane enzyme and other proteinic components, indicating adverse effects of CP on membrane integrity. The present results show that in contrast to CP treatment, dietary supplementation of FXO in control rats caused significant increase in the activities of membrane enzymes in the liver homogenate. Dietary FXO supplementation prior to and following CP treatment prevented/retarded CP-induced decrease in membrane enzymes in the tissue. The activity of lysosomal enzyme ACPase was significantly increased in liver homogenate by CP treatment. Alteration in ACPase activity demonstrate CP-induced loss of lysosomal function.<sup>
<xref ref-type="bibr" rid="bibr49-0960327111432502">49</xref>,<xref ref-type="bibr" rid="bibr50-0960327111432502">50</xref>
</sup> However, the CP-induced effect on lysosomal enzyme activity appeared to be ameliorated by dietary FXO supplementation.</p>
<p>To assess the functional aspects, the activities of various metabolic enzymes were determined under different experimental conditions. The activities of various enzymes involved in glycolysis, tricarboxylic acid (TCA) cycle, gluconeogenesis and hexose monophosphate (HMP)-shunt pathways were differentially altered by CP treatment and/or by FXO consumption. CP caused significant increase in LDH and decrease in MDH which was accompanied with a simultaneous increase in HK activity in liver tissue. Although the actual rates of glycolysis or TCA cycle were not determined, marked decrease in MDH activity appears to be due to CP-induced damage to mitochondria.<sup>
<xref ref-type="bibr" rid="bibr49-0960327111432502">49</xref>,<xref ref-type="bibr" rid="bibr50-0960327111432502">50</xref>
</sup> A marked increase in LDH activity with simultaneous decline in TCA cycle enzyme, MDH appears to be an adaptive cellular effect in energy metabolism from aerobic metabolism alternatively to anaerobic glycolysis due to CP-induced mitochondrial dysfunction.<sup>
<xref ref-type="bibr" rid="bibr49-0960327111432502">49</xref>
</sup>
</p>
<p>CP also altered the activities of enzymes of gluconeogenesis and HMP-shunt pathway. The activities of G6Pase, FBPase and G6PDH were profoundly decreased albeit to different extent. However, the activity of NADP ME was increased in the tissue. The present data indicate that CP caused differential effects on different enzymes of carbohydrate metabolism. FXO administration to CP-treated rats resulted in the overall improvement of carbohydrate metabolism as evident by higher activities of MDH and gluconeogenic enzymes in CPFXO as compared to CP group. FXO might have lowered the number of damaged mitochondria or other affected macromolecules or may have increased the number of normally active organelles or macromolecules.</p>
<p>Earlier reports reveal that heavy metals including CP<sup>
<xref ref-type="bibr" rid="bibr48-0960327111432502">48</xref>,<xref ref-type="bibr" rid="bibr51-0960327111432502">51</xref>,<xref ref-type="bibr" rid="bibr52-0960327111432502">52</xref>
</sup> exert their toxic effects by inducing the generation of ROS. A major cellular defense against ROS is provided by SOD and CAT, which together convert superoxide radicals first to H<sub>2</sub>O<sub>2</sub> and then to molecular oxygen and water. Other enzymes, e.g. GSH-Px, use thiol-reducing power of glutathione to reduce oxidized lipids and protein targets of ROS. However, oxidative stress can occur as a result of either increased ROS generation and/or decrease in antioxidant enzyme system. These antioxidant enzymes protect the cell against cytotoxic ROS. In agreement with the previous studies<sup>
<xref ref-type="bibr" rid="bibr4-0960327111432502">4</xref>,<xref ref-type="bibr" rid="bibr53-0960327111432502">53</xref>
</sup> present results show that CP enhanced LPO, an indicator of tissue injury and depleted protein thiols. CP administration to control rats caused severe damage to liver tissue most likely by ROS generation as apparent by perturbation in the antioxidant enzymes (SOD, CAT and GPx-SH) and total-SH content that lead to increased LPO. CP-treated rats fed on FXO-supplemented diet caused significant increase in SOD, CAT and GSH-Px activities accompanied by lower LPO values in liver tissue. The protection against CP by FXO can be attributed to its intrinsic biochemical and natural antioxidant properties. It appears that FXO enriched with ω-3 fatty acids enhanced resistance to free radical attack generated by CP administration. As indicated in <xref ref-type="fig" rid="fig3-0960327111432502">Figure 3</xref>, our results indicate an overall improvement in metabolic activities, lysosomal integrity and augmentation of antioxidant defenses in CP-treated FXO-fed rats.</p>
<fig id="fig3-0960327111432502" position="float">
<label>Figure 3.</label>
<caption>
<p>Cisplatin (CP)-induced alterations in cell metabolism, lysosomal integrity and oxidative stress and its amelioration by dietary flaxseed oil (FXO): a summary.</p>
</caption>
<graphic alternate-form-of="fig3-0960327111432502" xlink:href="10.1177_0960327111432502-fig3.tif"/>
</fig>
<p>We conclude that while CP elicited deleterious hepatotoxic effects by causing severe damage to the plasma membrane, mitochondria and other organelles by suppressing antioxidant defense mechanism, however these effects were ameliorated by dietary supplementation with FXO. Present study thus support the rationale that ω-3 fatty acids–enriched FXO may be effective dietary supplementation to maximize the clinical use of CP in the treatment of various malignancies without hepatotoxic and other side effects.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>Indian Council of Medical Research (ICMR), New Delhi, India, is acknowledged for the award of JRF (junior research fellowship)/SRF (senior research fellowship) to W.K. University Grants Commission (UGC) for the award of scholarship to A.N. and S.R. and financial support to the department from University Grants Commission (UGC-DRF) is also gratefully acknowledged.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327111432502">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict" id="fn2-0960327111432502">
<p>The authors declared no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327111432502">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Fundamental studies with cisplatin</article-title>. <source>Cancer</source> <year>1985</year>; <volume>55</volume>: <fpage>2303</fpage>–<lpage>2315</lpage>.</citation>
</ref>
<ref id="bibr2-0960327111432502">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cederbaum</surname>
<given-names>AI</given-names>
</name>
</person-group>. <article-title>Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1</article-title>. <source>Toxicol Sci</source> <year>2006</year>; <volume>89</volume>: <fpage>515</fpage>–<lpage>523</lpage>.</citation>
</ref>
<ref id="bibr3-0960327111432502">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iseri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ercan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gedik</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yuksel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alican</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Simvastatin attenuates cisplatin-induced kidney and liver damage in rats</article-title>. <source>Toxicology</source> <year>2007</year>; <volume>230</volume>: <fpage>256</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr4-0960327111432502">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naqshbandi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Rizwan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yusufi</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Studies on the protective effect of fish oil against cisplatin induced hepatotoxicity</article-title>. <source>Biol Med</source> <year>2011</year>; <volume>3</volume>: <fpage>86</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr5-0960327111432502">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naziroglu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karaoglu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aksoy</surname>
<given-names>AO</given-names>
</name>
</person-group>. <article-title>Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats</article-title>. <source>Toxicology</source> <year>2004</year>; <volume>195</volume>: <fpage>221</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr6-0960327111432502">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratibha</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sameer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rataboli</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Bhiwgade</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Dhume</surname>
<given-names>CY</given-names>
</name>
</person-group>. <article-title>Enzymatic studies of cisplatin-induced oxidative stress in hepatic tissue of rats</article-title>. <source>Eur J Pharmacol</source> <year>2006</year>; <volume>532</volume>: <fpage>290</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr7-0960327111432502">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iraz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ozerol</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gulec</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tasdemir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Idiz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fadillioglu</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat</article-title>. <source>Cell Biochem Funct</source> <year>2006</year>; <volume>24</volume>: <fpage>357</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr8-0960327111432502">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mansour</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Hafez</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Fahmy</surname>
<given-names>NM</given-names>
</name>
</person-group>. <article-title>Silymarin modulates cisplatin induced oxidative stress and hepatotoxicity in rats</article-title>. <source>J Biochem Mol Biol</source> <year>2006</year>; <volume>39</volume>: <fpage>656</fpage>–<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr9-0960327111432502">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Al Moundhri</surname>
<given-names>MS</given-names>
</name>
</person-group>. <article-title>Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research</article-title>. <source>Food Chem Toxicol</source> <year>2006</year>; <volume>44</volume>: <fpage>1173</fpage>–<lpage>1183</lpage>.</citation>
</ref>
<ref id="bibr10-0960327111432502">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Selection of agents for prevention of cisplatin-induced hepatotoxicity</article-title>. <source>Pharmacol Res</source> <year>2008</year>; <volume>57</volume>: <fpage>125</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr11-0960327111432502">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Priyamvada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Priyadarshini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arivarasu</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Farooq</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>S,</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>SA</given-names>
</name>
<etal/>
</person-group>. <article-title>Studies on the protective effect of dietary fish oil on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source> <year>2008</year>; <volume>78</volume>: <fpage>369</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr12-0960327111432502">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harper</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>TA</given-names>
</name>
</person-group>. <article-title>The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease</article-title>. <source>Arch Intern Med</source> <year>2001</year>; <volume>161</volume>: <fpage>2185</fpage>–<lpage>2192</lpage>.</citation>
</ref>
<ref id="bibr13-0960327111432502">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gebauer</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Psota</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Kris-Etherton</surname>
<given-names>PM</given-names>
</name>
</person-group>. <article-title>n-3 fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits</article-title>. <source>Am J Clin Nutr</source> <year>2006</year>; <volume>83</volume>: <fpage>1526S</fpage>–<lpage>1535S</lpage>.</citation>
</ref>
<ref id="bibr14-0960327111432502">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harper</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>DeFilipis</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>TA</given-names>
</name>
</person-group>. <article-title>Flaxseed oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans</article-title>. <source>J Nutr</source> <year>2006</year>; <volume>136</volume>: <fpage>83</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr15-0960327111432502">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chilton</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Rudel</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Parks</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Arm</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Seeds</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>Mechanisms by which botanical lipids affect inflammatory disorders</article-title>. <source>Am J Clin Nutr</source> <year>2008</year>; <volume>87</volume>: <fpage>498S</fpage>–<lpage>503S</lpage>.</citation>
</ref>
<ref id="bibr16-0960327111432502">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatia</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Patni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>AL</given-names>
</name>
</person-group>. <article-title>Prophylactic effect of flaxseed oil against radiation-induced hepatotoxicity in mice</article-title>. <source>Phytother Res</source> <year>2007</year>; <volume>21</volume>: <fpage>852</fpage>–<lpage>859</lpage>.</citation>
</ref>
<ref id="bibr17-0960327111432502">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khundmiri</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Asghar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Salim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yusufi</surname>
<given-names>AN</given-names>
</name>
</person-group>. <article-title>Effect of ischemia and reperfusion on enzymes of carbohydrate metabolism in rat kidney</article-title>. <source>J Nephrol</source> <year>2004</year>; <volume>17</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr18-0960327111432502">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crane</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Sols</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The association of particulate fractions of brain and other tissue homogenates</article-title>. <source>J Biol Chem</source> <year>1953</year>; <volume>203</volume>: <fpage>273</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr19-0960327111432502">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>A photometric adaptation of the Somogyi method for the determination of glucose</article-title>. <source>J Biol Chem</source> <year>1944</year>; <volume>153</volume>: <fpage>375</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr20-0960327111432502">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farooq</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yusufi</surname>
<given-names>ANK</given-names>
</name>
<name>
<surname>Mahmood</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Effect of fasting on enzymes of carbohydrate metabolism and brush border membrane in rat intestine</article-title>. <source>Nutr Res</source> <year>2004</year>; <volume>24</volume>: <fpage>407</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr21-0960327111432502">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marklund</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marklund</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Involvement of the superoxide anion radical in the auto oxidation of pyrogallol and a convenient assay for superoxide dismutase</article-title>. <source>Eur J Biochem</source> <year>1974</year>; <volume>47</volume>: <fpage>469</fpage>–<lpage>474</lpage>.</citation>
</ref>
<ref id="bibr22-0960327111432502">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giri</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Athar</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Porphyrin—mediated photosensitization has a weak tumor promoting activity in mouse skin: possible role of in-situ generated reactive oxygen species</article-title>. <source>Carcinogenes</source> <year>1996</year>; <volume>17</volume>: <fpage>2023</fpage>–<lpage>2028</lpage>.</citation>
</ref>
<ref id="bibr23-0960327111432502">
<label>23</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Flohe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gunzler</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Assays of glutathione peroxidase</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>SP</surname>
<given-names>Colowick,</given-names>
</name>
<name>
<surname>NO</surname>
<given-names>Kaplan</given-names>
</name>
</person-group> (eds) <source>Methods enzymology</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>1984</year>, pp. <fpage>114</fpage>–<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr24-0960327111432502">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sedlak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>RH</given-names>
</name>
</person-group>. <article-title>Estimation of total protein bound and non protein bound SH groups in tissue with Ellman’s reagent</article-title>. <source>Ann Biochem</source> <year>1968</year>; <volume>2</volume>: <fpage>192</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr25-0960327111432502">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohkawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohishi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yagi</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction</article-title>. <source>Ann Biochem</source> <year>1979</year>; <volume>95</volume>: <fpage>351</fpage>–<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr26-0960327111432502">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Barri</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>SV</given-names>
</name>
</person-group>. <article-title>Oxidant mechanisms on gentamicin nephrotoxicity</article-title>. <source>Ren Fail</source> <year>1999</year>; <volume>21</volume>: <fpage>433</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr27-0960327111432502">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakashima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maehara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kohnoe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Katsuta</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Histologic differentiation and chemosensitivity of human head and neck squamous cell carcinomas</article-title>. <source>Head Neck</source> <year>1990</year>; <volume>12</volume>: <fpage>406</fpage>–<lpage>410</lpage>.</citation>
</ref>
<ref id="bibr28-0960327111432502">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nazneen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abid</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Razzaque</surname>
<given-names>MS</given-names>
</name>
</person-group>. <article-title>Cisplatin-associated nephrotoxicity and pathological events</article-title>. <source>Contrib Nephrol</source> <year>2005</year>; <volume>148</volume>: <fpage>107</fpage>–<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr29-0960327111432502">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winston</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Safirstein</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Reduced renal flow in early cisplatin-induced acute renal failure in the rat</article-title>. <source>Am J Physiol</source> <year>1985</year>; <volume>24</volume>: <fpage>F490</fpage>–<lpage>F496</lpage>.</citation>
</ref>
<ref id="bibr30-0960327111432502">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greggi Antunes</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Darin</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats</article-title>. <source>Pharmacol Res</source> <year>2000</year>; <volume>41</volume>: <fpage>405</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr31-0960327111432502">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chirino</surname>
<given-names>YI</given-names>
</name>
<name>
<surname>Hernandez-Pando</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pedraza-Chaveri</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats</article-title>. <source>BMC Pharmacol</source> <year>2004</year>; <volume>4</volume>: <fpage>20</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr32-0960327111432502">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hesketh</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Twaddell</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>A possible role for cisplatin (DDP) in the transient hepatic enzyme elevation noted after ondansetron administration</article-title>. <source>Proc Am Assoc Clin Oncol</source> <year>1990</year>; <volume>9</volume>: <fpage>323</fpage>.</citation>
</ref>
<ref id="bibr33-0960327111432502">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vermorken</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Pinedo</surname>
<given-names>HM</given-names>
</name>
</person-group>. <article-title>Gastrointestinal toxicity of <italic>cis</italic> diamminedichloroplatinum (II)</article-title>. <source>Neth J Med</source> <year>1982</year>; <volume>25</volume>: <fpage>270</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr34-0960327111432502">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lippard</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Cisplatin: from DNA damage to cancer chemotherapy</article-title>. <source>Prog Nucleic Acids Res Mol Biol</source> <year>2001</year>; <volume>67</volume>: <fpage>93</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr35-0960327111432502">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadowitz</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Dabrowiak</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Goodisman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tacka</surname>
<given-names>KA,</given-names>
</name>
<name>
<surname>Aktas</surname>
<given-names>MK</given-names>
</name>
<etal/>
</person-group>. <article-title>Kinetics of cisplatin binding to cellular DNA and modulations by thiolblocking agents and thiol drugs</article-title>. <source>Drug Metab Dispos</source> <year>2002</year>; <volume>30</volume>: <fpage>183</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr36-0960327111432502">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jordan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Carmo-Fonseca</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Molecular mechanisms involved in cisplatin cytotoxicity</article-title>. <source>Cell Mol Life Sci</source> <year>2000</year>; <volume>57</volume>: <fpage>1229</fpage>–<lpage>1235</lpage>.</citation>
</ref>
<ref id="bibr37-0960327111432502">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Sayyad</surname>
<given-names>HI</given-names>
</name>
<name>
<surname>Ismail</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Shalaby</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Abou-El-Magd</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Gaur</surname>
<given-names>RL,</given-names>
</name>
<name>
<surname>Fernando</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Histopathological effects of cisplatin, doxorubicin and 5-flourouracil(5-FU) on the liver of male albino rats</article-title>. <source>Int J Biol Sci</source> <year>2009</year>; <volume>5</volume>: <fpage>466</fpage>–<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr38-0960327111432502">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karadeniz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simsek</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Karakus</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Yildirim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kara</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Can</surname>
<given-names> I</given-names>
</name>
<etal/>
</person-group>. <article-title>Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin</article-title>. <source>Oxid Med Cell Longev</source> <year>2011</year>; <fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr39-0960327111432502">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blakley</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Doolittle</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Muldoon</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Dickey</surname>
<given-names>DT</given-names>
</name>
</person-group>. <article-title>Strategies for prevention of toxicity caused by platinum-based chemotherapy</article-title>. <source>Laryngoscope</source> <year>2002</year>; <volume>112</volume>: <fpage>1997</fpage>–<lpage>2001</lpage>.</citation>
</ref>
<ref id="bibr40-0960327111432502">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leitao</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Blakley</surname>
<given-names>BW</given-names>
</name>
</person-group>. <article-title>Quantification of sodium thiosulphate protection on cisplatin-induced toxicities</article-title>. <source>J Otolaryngol</source> <year>2003</year>; <volume>32</volume>: <fpage>146</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr41-0960327111432502">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fetoni</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Sergi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ferraresi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paludetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Troiani</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity</article-title>. <source>Acta Otolaryngol</source> <year>2004</year>; <volume>124</volume>: <fpage>421</fpage>–<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr42-0960327111432502">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Speck</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Lauterburgh</surname>
<given-names>BH</given-names>
</name>
</person-group>. <article-title>Fish oil protects mice against acetaminophen hepatotoxocity in vivo</article-title>. <source>Hepatology</source> <year>1991</year>; <volume>13</volume>: <fpage>557</fpage>–<lpage>561</lpage>.</citation>
</ref>
<ref id="bibr43-0960327111432502">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>FW</given-names>
</name>
</person-group>. <article-title>Fish oil protects against ethanol-induced gastric mucosal injury in rats</article-title>. <source>Dig Dis Sci</source> <year>1992</year>; <volume>37</volume>: <fpage>636</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr44-0960327111432502">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdel-Moneim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dkhil</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Al-Quraishy</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>The redox status in rats treated with flaxseed oil and lead-induced hepatotoxicity</article-title>. <source>Biol Trace Elem Res</source> <year>2011</year>; <volume>143</volume>: <fpage>457</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr45-0960327111432502">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdel-Moniem</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Dkhil</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Al-Quraishy</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Protective role of flaxseed oil against lead acetate induced oxidative stress in testes of adult rats</article-title>. <source>Afr J Biotechnol</source> <year>2010</year>; <volume>9</volume>: <fpage>7216</fpage>–<lpage>7223</lpage>.</citation>
</ref>
<ref id="bibr46-0960327111432502">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdel-Moniem</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Dkhil</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Al-Quraishy</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>The potential role of flaxseed oil on lead acetate induced kidney injure in adult male albino rats</article-title>. <source>Afr J Biotechnol</source> <year>2011</year>; <volume>10</volume>: <fpage>1436</fpage>–<lpage>1451</lpage>.</citation>
</ref>
<ref id="bibr47-0960327111432502">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arany</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Safirstein</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Cisplatin nephrotoxicity</article-title>. <source>Semin Nephrol</source> <year>2003</year>; <volume>23</volume>: <fpage>460</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr48-0960327111432502">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yusufi</surname>
<given-names>ANK</given-names>
</name>
<name>
<surname>Mahmood</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Effect of cisplatin on renal brush border membrane enzymes and phosphate transport</article-title>. <source>Hum Exp Toxicol</source> <year>2004</year>; <volume>23</volume>: <fpage>547</fpage>–<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr49-0960327111432502">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhlmann</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Burkhardt</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kohler</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application</article-title>. <source>Nephrol Dial Transplant</source> <year>1997</year>; <volume>12</volume>: <fpage>2478</fpage>–<lpage>2480</lpage>.</citation>
</ref>
<ref id="bibr50-0960327111432502">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Courjault-Gautier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Le Grimellec</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Giocondi</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Toutain</surname>
<given-names>HJ</given-names>
</name>
</person-group>. <article-title>Modulation of sodium coupled uptake and membrane fluidity by cisplatin in renal proximal tubular cells in primary culture and BBM vesicles</article-title>. <source>Kidney Int</source> <year>1995</year>; <volume>47</volume>: <fpage>1048</fpage>–<lpage>1056</lpage>.</citation>
</ref>
<ref id="bibr51-0960327111432502">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baligha</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Baliga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>SV</given-names>
</name>
</person-group>. <article-title>Invitro and invivo evidence suggesting a role of iron in cisplatin-induced nephrotoxicity</article-title>. <source>Kidney Int</source> <year>1998</year>; <volume>53</volume>: <fpage>394</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr52-0960327111432502">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banday</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Priyamvada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Farooq</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yusufi</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Effect of uranyl nitrate on enzymes of carbohydrate metabolism and brush border membrane in different kidney tissues</article-title>. <source>Food Chem Toxicol</source> <year>2008</year>; <volume>46</volume>: <fpage>2080</fpage>–<lpage>2088</lpage>.</citation>
</ref>
<ref id="bibr53-0960327111432502">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Priyamvada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Farooq</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yusufi</surname>
<given-names>AN</given-names>
</name>
</person-group>. <article-title>Studies on the protective effect of green tea extract against cisplatin induced nephrotoxicity</article-title>. <source>Pharmacol Res</source> <year>2009</year>; <volume>60</volume>: <fpage>382</fpage>–<lpage>391</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>